🔬 FDA ISTAND Program

← Back to Qualification Pathways

Overview

The FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) program is a specialized qualification pathway within the Drug Development Tool (DDT) framework designed specifically for novel technologies including organ-on-chip systems, advanced organoid platforms, microphysiological systems, and computational drug discovery tools.

ISTAND represents FDA's commitment to modernizing drug development by qualifying tools that have scientific promise and biological relevance but lack extensive regulatory history. This pathway enables companies to obtain formal FDA confirmation of method validity for specific contexts of use, allowing reuse across multiple development programs.

When to Use ISTAND

• Technology is truly innovative with limited regulatory precedent
• Application to drug development (not cosmetics or chemicals)
• Scientific evidence supports biological relevance to human response
• Method addresses genuine unmet need in drug development
• Organization can commit 3-4 years and $3-8M to validation program
• Goal is reusable qualification across multiple drug programs
• Seeking competitive advantage through regulatory precedent

The ISTAND Process

Step 1: Pre-Submission Meeting (Highly Recommended)

Meet with FDA CDER Biomarker Qualification Team. Present preliminary data on 20-50 compounds, explain the unmet need, describe the platform's biological rationale, and discuss your proposed validation strategy. FDA provides critical guidance on data requirements, sample size recommendations, and pathway feasibility. Success rate for ISTAND qualification improves from 60% to 80%+ when preceded by pre-submission meeting.

Step 2: Qualification Plan Development

Prepare comprehensive Qualification Plan including: (1) Context of Use statement defining specific intended use, (2) Scientific rationale explaining biological relevance, (3) Preliminary data demonstrating proof-of-concept, (4) Proposed validation strategy with detailed experimental design, (5) Statistical analysis plan with acceptance criteria, (6) Reference compound selection strategy with 100-500+ compound list, and (7) Timeline with realistic milestones.

Step 3: FDA Plan Review

Submit qualification plan to FDA CDER Biomarker Qualification Team. FDA conducts 3-6 month comprehensive review, providing written comments and recommendations. Applicant refines approach based on feedback, addresses FDA concerns, and confirms modified strategy is acceptable before major validation investment.

Step 4: Validation Study Execution

Execute comprehensive multi-site validation studies per FDA-approved protocol. Test 100-500+ reference compounds with known clinical outcomes. Establish reproducibility across 2-3+ independent laboratories. Conduct intra-assay and inter-assay variability studies. Document all standard operating procedures. Generate statistical summaries of performance metrics (sensitivity, specificity, predictive values).

Step 5: Full Package Submission

Compile and submit complete qualification dossier to FDA containing: (1) All raw validation data and statistical analyses, (2) Detailed technical documentation and SOPs, (3) Comparison with traditional methods or reference standards, (4) Mechanistic justification for biological relevance, (5) Discussion of limitations and conditions of use, and (6) Regulatory justification for qualification.

Step 6: FDA Full Review

CDER Biomarker Qualification Team and CDER leadership conduct comprehensive evaluation of submitted package (9-18 months). Team may request additional data, supplemental studies, or clarifications. Applicant responds promptly to FDA Informational Requests. Team assesses whether platform meets FDA criteria for qualification: relevance, reliability, transferability, and regulatory decision acceptance.

Step 7: Qualification Letter

Upon successful review, FDA issues Qualification Letter confirming the tool's acceptability for the specified Context of Use. Letter specifies: (1) Validated endpoints and their predictive value, (2) Performance characteristics and metrics, (3) Conditions and limitations of use, (4) Data supporting qualification, and (5) Recommendation for use in INDs and NDAs. Qualification is immediately available for use in regulatory submissions without re-demonstration of validity.

Total Timeline: 3-4 years from pre-submission meeting to qualification letter

Key Requirements for ISTAND Qualification

Success Stories: Methods Achieving ISTAND Qualification

Emulate Liver-Chip (2023)

First organ-on-chip system to receive FDA ISTAND qualification. Validated for predicting drug-induced liver injury (DILI) in small molecule drugs during preclinical development. Emulate conducted rigorous multi-year validation with 870 compounds across academic partner laboratories (MIT, University of Pennsylvania) and industry partners. Now integrated into drug development workflows at Roche, GSK, AbbVie, and other major pharmaceutical companies. Qualification letter explicitly endorsed use in INDs and safety assessment packages.

Recursion AI Platform (In Development)

AI-powered phenotypic screening platform pursuing ISTAND qualification for target identification. Represents novel computational NAM pathway using machine learning to identify drug targets from cellular phenotypes. Strong preliminary validation data with published results demonstrating superior performance to traditional assays in specific indication areas.

CN Bio PhysioMimix (In Qualification)

3D human liver tissue model currently undergoing ISTAND qualification for hepatotoxicity assessment. Multi-company consortium (CN Bio, AstraZeneca, Roche, academic partners) collectively developing validation dataset.

ISTAND vs Other Qualification Pathways

Budget and Resource Requirements

• Regulatory Consulting: $300-500K (external regulatory strategy and FDA interface)
• Contract Laboratory Support: $1-2M (multi-site validation at independent CROs)
• Reference Compounds: $500K-1M (sourcing, characterization, shipment)
• Personnel (3-4 years): $1-2M (internal scientific staff, 2-3 FTE)
• Statistical Analysis & Data Management: $150-300K
• Quality Assurance / GLP Support: $200-400K
• Total Estimated Budget Range: $3-8M over 3-4 years

Implementation Roadmap

1. Feasibility Assessment (0-3 months): Validate preliminary data on 20-50 compounds; confirm scientific rationale; assess resource capability
2. Schedule Pre-Submission Meeting (3-6 months): Submit Type C meeting request to CDER Biomarker Team; prepare presentation materials
3. Pre-Submission Meeting (6-9 months): Meet with FDA; receive guidance on pathway strategy and data requirements
4. Refine Validation Strategy (9-12 months): Incorporate FDA feedback; finalize protocol; identify contract labs
5. Qualification Plan Preparation (10-15 months): Prepare comprehensive Qualification Plan per FDA guidance
6. Submit to FDA (15 months): Submit Qualification Plan to CDER
7. FDA Plan Review (15-21 months): FDA reviews; provide comments; applicant revises
8. Initiate Validation Studies (18-24 months): Begin inter-laboratory validation at contract sites
9. Execute Full Validation (24-36 months): Complete testing of 100-500+ compounds; ongoing data analysis
10. Prepare Regulatory Dossier (36-42 months): Compile all data, analyses, documentation
11. Submit Full Package (42-45 months): Submit complete qualification dossier to FDA
12. FDA Review (45-60 months): FDA comprehensive review (9-18 months)
13. Receive Qualification Letter (54-60 months): FDA issues final Qualification Letter

Resources and Further Information

• FDA Drug Development Tool Qualification Program - Official program information
• CDER Drug Development Tool Office - Contact information for FDA engagement
• Regulatory Hub - Overview of all qualification pathways
• Technology Overview - Learn about organ-on-chip and other NAMs platforms
• Science Section - Detailed information on NAMs technologies

← Back to Qualification Pathways